Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inavolisib + eribulin
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Inavolisib + eribulin is a combination therapy being investigated for the treatment of advanced triple-negative breast cancer (TNBC) harboring PIK3CA mutations. Inavolisib (Itovebi) is a potent, selective, and orally bioavailable PI3Kα inhibitor that specifically targets the p110α isoform and induces the degradation of mutant p110α. Eribulin (Halaven) is a synthetic analogue of halichondrin B that acts as a microtubule dynamics inhibitor, specifically binding to the plus ends of microtubules to inhibit growth. This combination aims to provide synergistic antitumor activity by simultaneously inhibiting the PI3K signaling pathway, which is frequently mutated in TNBC, and disrupting mitotic progression. The combination is currently being evaluated in a Phase II clinical trial (NCT06344104) sponsored by investigator Hu Hai.
- Other names
- inavolisib + eribulin mesylate
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on inavolisib + eribulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inavolisib + eribulin.